![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Akribion Genomics
Company Type: CRO
Main focus: Discovery and engineering of novel nucleases
Company stage: Pre-clinical
Diseases: Cancer
Genome-editing tool: Proprietary G-dases® nucleases
Funding stage: sub-section of BRAIN Biotech AG (IPO: BNN)
Location: Zwingenberg, Germany
Website: https://www.akribion-genomics.com/
Pipeline:
Partners: BRAIN Biotech AG
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Akribion_Genomics_33483d0fa7_66fb9e51fa.jpg)
As a brand name of BRAIN Biotech AG, Akribion Genomics focuses on developing novel CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome-editing tools, powered by the BRAIN Biotech AG BioIncubator. Akribion Genomics’ CRISPR-based gene-editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology and Agriculture.